Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity

Examine Setmelanotide use in patients with rare genetic variants that disrupt the melanocortin pathway. RECENT FINDINGS: Between February 2017 and September 2018, 10 participants with pro-opiomelanocortin (POMC)/ proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency and 11 participants wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Trapp, Christine M., Censani, Marisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Special Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973437/
https://www.ncbi.nlm.nih.gov/pubmed/36722447
http://dx.doi.org/10.1097/MED.0000000000000798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973437/
https://www.ncbi.nlm.nih.gov/pubmed/36722447
http://dx.doi.org/10.1097/MED.0000000000000798

Ejemplares similares